Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.
about
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseRoflumilast: a review of its use in the treatment of COPDAppropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawalRisk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study.Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia.The management of community-acquired pneumonia in the elderlyCosts and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia.Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Novel aspects of pathogenesis and regeneration mechanisms in COPDGlucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function.Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population.Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Cohort StudyBlood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.The Skeletal Effects of Inhaled Glucocorticoids.A role of indacaterol in chronic obstructive pulmonary disease management: a turning point or crossroads?The association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPD.Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPDEvaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.Inhaled corticosteroids for chronic obstructive pulmonary disease.Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.Recent advances in COPD disease management with fixed-dose long-acting combination therapies.Safety considerations of inhaled corticosteroids in the elderly.Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review.Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and Risk of Pneumonia: A Nested Case-Control Population-based Study in Lazio (Italy)-The OUTPUL Study.Journal Club: Inhaled Corticosteroids- Refining Our Understanding of Their Role in Maintenance Treatment for COPD.Tailoring of corticosteroids in COPD management.Pneumococcal vaccination and chronic respiratory diseases.Triple Therapy in COPD: What We Know and What We Don't.Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease.The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study
P2860
Q24197989-1FA98306-FF99-47FC-A879-03187ED877B0Q26770501-041EC689-E67D-420A-BCB6-27EC689A2856Q28074169-0CA352E8-0F6B-4037-AD30-0321CC4DD890Q33689926-C19A289D-1ED4-4339-A15C-872D2AAC146EQ33709357-D967D920-D2C4-43B6-8A49-41645A661E65Q33915736-584B4A2E-CA9E-4B67-B450-45061639A200Q33933904-EDAA2E26-0363-43BC-9ED0-D749EADABE7DQ34003435-5682B317-ED7C-4823-87F1-85DC01FFA72AQ35665638-AEC88BF1-04D6-4707-8A5C-E03C57B6DC91Q35762822-900A0A9B-287F-4B00-AC33-72E51D1FDC2BQ35892486-107904E3-BBAB-486F-BEC0-674AE10A83C8Q36206896-419892F0-C6D1-47C2-A4D4-7BF217221181Q36302882-E655364E-79F9-4C6E-AA3F-A03E280253EDQ36885279-9B8155ED-CB0D-449F-A07D-756C46D67F56Q37128069-EC409528-A19E-4714-997F-87B4E1004548Q37259422-1AD1EBB3-D4E2-4EAC-B441-BB0885934DAFQ37614090-F497BCE3-3DBA-42BC-A65E-8D09D13D2FC5Q38125210-E7276E97-5832-4B9A-AF33-D89A207ED75CQ38153757-F1D768E0-3B6C-4614-808B-9B80DA0A7671Q38187182-9AAE03EE-BE51-4628-B289-572154CDC90AQ38209841-6AD2FED9-95E8-4D85-A8A9-301F99AE64FEQ38248458-E0D0E4FC-05C2-4572-AD12-DD9EE1CC833FQ38550921-7DE90F63-C36A-4DDB-AB37-8A6B82B9B088Q38740312-C36484FA-60CB-422E-BE76-9909DFE6EA1BQ38844053-BE57680A-7453-47ED-AC7B-3F51A3D19535Q40244225-CF346234-C168-468C-985F-72EACC71BF6EQ41434144-FC17301B-955E-42AF-A88A-CC44193EA2A2Q42753079-ED5F03C0-FBAE-4A26-B676-CA24C40E47A0Q47162758-6E466BE7-9B1C-417B-BB76-4C0DDA6045C5Q48335044-00CA7CC8-A1CF-4228-8892-2A567D170EFDQ52649905-4E3F3FD4-124A-4262-9B4D-895F4DC79C0CQ54985799-697C3051-EA1D-4FE1-A15C-7AA2CB950921Q57492222-1B3E707A-7C47-4349-8B9B-7EF3C1F075A0
P2860
Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Inhaled corticosteroid use in ...... spective claims data analysis.
@ast
Inhaled corticosteroid use in ...... spective claims data analysis.
@en
type
label
Inhaled corticosteroid use in ...... spective claims data analysis.
@ast
Inhaled corticosteroid use in ...... spective claims data analysis.
@en
prefLabel
Inhaled corticosteroid use in ...... spective claims data analysis.
@ast
Inhaled corticosteroid use in ...... spective claims data analysis.
@en
P2093
P2860
P356
P1476
Inhaled corticosteroid use in ...... spective claims data analysis.
@en
P2093
Barbara P Yawn
Haijun Tian
Kristijan H Kahler
Steve Arcona
Yunfeng Li
P2860
P304
P356
10.2147/COPD.S42366
P407
P577
2013-06-27T00:00:00Z